製品の概要

  • 製品名

    Human Pro-Collagen I alpha 1 ELISA Kit
    Collagen I キット 製品一覧
  • 検出方法

    Colorimetric
  • 再現性

    Intra-Assay(同時再現性)
    サンプル N 平均値 SD CV%
    Serum 8 1.8%
    Inter-Assay(日差再現性)
    サンプル N 平均値 SD CV%
    Serum 3 3%
  • サンプルの種類

    Cell culture supernatant, Serum, Plasma, Cell culture extracts, Tissue Extracts
  • アッセイタイプ

    Sandwich (quantitative)
  • 検出感度

    5.3 pg/ml
  • 検出範囲

    39.06 pg/ml - 2000 pg/ml
  • 添加回収試験

    特定サンプルでの回収試験
    サンプルの種類 平均 % 測定範囲
    Serum 93 91% - 94%
    Cell culture media 99 97% - 101%
    Heparin Plasma 101 94% - 107%
    EDTA Plasma 108 105% - 114%
    Citrate Plasma 106 102% - 110%

  • 全工程の試験時間

    1h 30m
  • ステップ

    One step assay
  • 種交差性

    交差種: Human
    非交差種: Mouse, Rat, Cow
  • 製品の概要

    Pro-Collagen I alpha 1 in vitro SimpleStep ELISA® (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of human Pro-Collagen I alpha 1 protein in serum, plasma, cell culture supernatants, and cell and tissue extract samples.


    The SimpleStep ELISA® employs an affinity tag labeled capture antibody and a reporter conjugated detector antibody which immunocapture the sample analyte in solution. This entire complex (capture antibody/analyte/detector antibody) is in turn immobilized via immunoaffinity of an anti-tag antibody coating the well. To perform the assay, samples or standards are added to the wells, followed by the antibody mix. After incubation, the wells are washed to remove unbound material.  TMB substrate is added and during incubation is catalyzed by HRP, generating blue coloration. This reaction is then stopped by addition of Stop Solution completing any color change from blue to yellow. Signal is generated proportionally to the amount of bound analyte and the intensity is measured at 450 nm. Optionally, instead of the endpoint reading, development of TMB can be recorded kinetically at 600 nm.


    Sensitivity:
    Samples diluted in Sample Diluent NS MDD = 5.6 pg/mL
    Samples diluted in 1X Cell Extraction Buffer PTR MDD = 5.3 pg/mL

  • 特記事項

    Type I collagen is the most abundant structural protein of connective tissues such as skin, bone and tendon. It is synthesized as a pro-collagen molecule that is characterized by a 300 nm triple helical domain flanked by globular N- and C-terminal propeptides. Specifically, human Pro-Collagen I alpha 1 consists of a signal peptide (amino acids (aa) 1-22), a propeptide (aa 23-161), the mature chain (aa 162-1218), and another propeptide (aa 1219 – 1464). The non-helical propeptides are removed by procollagen N- and C-proteinase activities so that the mature triple helices can self-assemble into collagen fibrils that provide tensile strength to tissues.

  • アプリケーション

    適用あり: Sandwich ELISAmore details
  • 試験プラットフォーム

    Pre-coated microplate (12 x 8 well strips)

製品の特性

  • 保存方法

    Store at +4°C. Please refer to protocols.
  • 内容 1 x 96 tests
    10X Human Pro-Collagen I alpha 1 Capture Antibody 1 x 600µl
    10X Human Pro-Collagen I alpha 1 Detector Antibody 1 x 600µl
    10X Wash Buffer PT (ab206977) 1 x 20ml
    50X Cell Extraction Enhancer Solution (ab193971) 1 x 1ml
    5X Cell Extraction Buffer PTR (ab193970) 1 x 10ml
    Antibody Diluent CPI 1 x 6ml
    Human Pro-Collagen I alpha 1 Lyophilized Recombinant Protein 2 vials
    Plate Seals 1 unit
    Sample Diluent NS 1 x 50ml
    SimpleStep Pre-Coated 96-Well Microplate (ab206978) 1 unit
    Stop Solution 1 x 12ml
    TMB Development Solution 1 x 12ml
  • 研究分野

  • 機能

    Type I collagen is a member of group I collagen (fibrillar forming collagen).
  • 組織特異性

    Forms the fibrils of tendon, ligaments and bones. In bones the fibrils are mineralized with calcium hydroxyapatite.
  • 関連疾患

    Defects in COL1A1 are the cause of Caffey disease (CAFFD) [MIM:114000]; also known as infantile cortical hyperostosis. Caffey disease is characterized by an infantile episode of massive subperiosteal new bone formation that typically involves the diaphyses of the long bones, mandible, and clavicles. The involved bones may also appear inflamed, with painful swelling and systemic fever often accompanying the illness. The bone changes usually begin before 5 months of age and resolve before 2 years of age.
    Defects in COL1A1 are a cause of Ehlers-Danlos syndrome type 1 (EDS1) [MIM:130000]; also known as Ehlers-Danlos syndrome gravis. EDS is a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDS1 is the severe form of classic Ehlers-Danlos syndrome.
    Defects in COL1A1 are the cause of Ehlers-Danlos syndrome type 7A (EDS7A) [MIM:130060]; also known as autosomal dominant Ehlers-Danlos syndrome type VII. EDS is a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDS7A is marked by bilateral congenital hip dislocation, hyperlaxity of the joints, and recurrent partial dislocations.
    Defects in COL1A1 are a cause of osteogenesis imperfecta type 1 (OI1) [MIM:166200]. A dominantly inherited connective tissue disorder characterized by bone fragility and blue sclerae. Osteogenesis imperfecta type 1 is non-deforming with normal height or mild short stature, and no dentinogenesis imperfecta.
    Defects in COL1A1 are a cause of osteogenesis imperfecta type 2A (OI2A) [MIM:166210]; also known as osteogenesis imperfecta congenita. A connective tissue disorder characterized by bone fragility, with many perinatal fractures, severe bowing of long bones, undermineralization, and death in the perinatal period due to respiratory insufficiency.
    Defects in COL1A1 are a cause of osteogenesis imperfecta type 3 (OI3) [MIM:259420]. A connective tissue disorder characterized by progressively deforming bones, very short stature, a triangular face, severe scoliosis, grayish sclera, and dentinogenesis imperfecta.
    Defects in COL1A1 are a cause of osteogenesis imperfecta type 4 (OI4) [MIM:166220]; also known as osteogenesis imperfecta with normal sclerae. A connective tissue disorder characterized by moderately short stature, mild to moderate scoliosis, grayish or white sclera and dentinogenesis imperfecta.
    Genetic variations in COL1A1 are a cause of susceptibility to osteoporosis (OSTEOP) [MIM:166710]; also known as involutional or senile osteoporosis or postmenopausal osteoporosis. Osteoporosis is characterized by reduced bone mass, disruption of bone microarchitecture without alteration in the composition of bone. Osteoporotic bones are more at risk of fracture.
    Note=A chromosomal aberration involving COL1A1 is found in dermatofibrosarcoma protuberans. Translocation t(17;22)(q22;q13) with PDGF.
  • 配列類似性

    Belongs to the fibrillar collagen family.
    Contains 1 fibrillar collagen NC1 domain.
    Contains 1 VWFC domain.
  • 翻訳後修飾

    Proline residues at the third position of the tripeptide repeating unit (G-X-Y) are hydroxylated in some or all of the chains. Proline residues at the second position of the tripeptide repeating unit (G-X-Y) are hydroxylated in some of the chains.
    O-linked glycan consists of a Glc-Gal disaccharide bound to the oxygen atom of a post-translationally added hydroxyl group.
  • 細胞内局在

    Secreted > extracellular space > extracellular matrix.
  • Information by UniProt
  • 別名

    • Alpha 1 type I collagen
    • Alpha 2 type I collagen
    • alpha 2 type I procollagen
    • alpha 2(I) procollagen
    • alpha 2(I)-collagen
    • Alpha-1 type I collagen
    • alpha1(I) procollagen
    • CO1A1_HUMAN
    • COL1A1
    • COL1A2
    • collagen alpha 1 chain type I
    • Collagen alpha-1(I) chain
    • collagen alpha-1(I) chain preproprotein
    • Collagen I alpha 1 polypeptide
    • Collagen I alpha 2 polypeptide
    • collagen of skin, tendon and bone, alpha-1 chain
    • collagen of skin, tendon and bone, alpha-2 chain
    • Collagen type I alpha 1
    • Collagen type I alpha 2
    • EDSC
    • OI1
    • OI2
    • OI3
    • OI4
    • pro-alpha-1 collagen type 1
    • type I proalpha 1
    • Type I procollagen
    • type I procollagen alpha 1 chain
    see all
  • 参照データベース

アプリケーション

Our Abpromise guarantee covers the use of ab210966 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
Sandwich ELISA Use at an assay dependent concentration.

画像

  • SimpleStep ELISA technology allows the formation of the antibody-antigen complex in one single step, reducing assay time to 90 minutes. Add samples or standards and antibody mix to wells all at once, incubate, wash, and add your final substrate. See protocol for a detailed step-by-step guide.

     

  • Background-subtracted data values (mean +/- SD) are graphed.

  • Background-subtracted data values (mean +/- SD) are graphed.

  • The concentrations of Pro-Collagen I alpha 1 were measured in duplicates, interpolated from the Pro-Collagen I alpha 1 standard curves and corrected for sample dilution. Undiluted samples are as follows: serum 1%, plasma (citrate) 1%, plasma (EDTA) 1%, and plasma (heparin) 1%. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean Pro-Collagen I alpha 1 concentration was determined to be 142.1 ng/mL in serum, 135.9 ng/mL in plasma (citrate), 112.1 ng/mL in plasma (EDTA) and 102.1 ng/mL in plasma (heparin).

  • The concentrations of Pro‑Collagen I alpha 1 were measured in duplicate and interpolated from the Pro‑Collagen I alpha 1 standard curve and corrected for sample dilution. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean Pro-Collagen I alpha 1 concentration was determined to be 1.62 ng/mL in IMR-90 extract.

  • Interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean Pro-Collagen I alpha 1 concentration was determined to be 197.3 ng/mL with a range of 113.0 – 417 ng/mL.

プロトコール

参考文献

This product has been referenced in:

  • Chao L  et al. miR-96 promotes collagen deposition in keloids by targeting Smad7. Exp Ther Med 17:773-781 (2019). Read more (PubMed: 30651862) »
  • Schröder A  et al. Impact of Mechanical Load on the Expression Profile of Synovial Fibroblasts from Patients with and without Osteoarthritis. Int J Mol Sci 20:N/A (2019). Read more (PubMed: 30704030) »
See all 10 Publications for this product

レビューと Q&A

There are currently no Customer reviews or Questions for ab210966.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

登録